207 related articles for article (PubMed ID: 38559562)
1. SKping cell cycle regulation: role of ubiquitin ligase SKP2 in hematological malignancies.
William JNG; Dhar R; Gundamaraju R; Sahoo OS; Pethusamy K; Raj AFPAM; Ramasamy S; Alqahtani MS; Abbas M; Karmakar S
Front Oncol; 2024; 14():1288501. PubMed ID: 38559562
[TBL] [Abstract][Full Text] [Related]
2. Dysregulated expression of SKP2 and its role in hematological malignancies.
Kulinski M; Achkar IW; Haris M; Dermime S; Mohammad RM; Uddin S
Leuk Lymphoma; 2018 May; 59(5):1051-1063. PubMed ID: 28797197
[TBL] [Abstract][Full Text] [Related]
3. E3 ubiquitin ligase Skp2 as an attractive target in cancer therapy.
Hao Z; Huang S
Front Biosci (Landmark Ed); 2015 Jan; 20(3):474-90. PubMed ID: 25553462
[TBL] [Abstract][Full Text] [Related]
4. Regulation of neddylation and deneddylation of cullin1 in SCFSkp2 ubiquitin ligase by F-box protein and substrate.
Bornstein G; Ganoth D; Hershko A
Proc Natl Acad Sci U S A; 2006 Aug; 103(31):11515-20. PubMed ID: 16861300
[TBL] [Abstract][Full Text] [Related]
5. Control of the SCF(Skp2-Cks1) ubiquitin ligase by the APC/C(Cdh1) ubiquitin ligase.
Bashir T; Dorrello NV; Amador V; Guardavaccaro D; Pagano M
Nature; 2004 Mar; 428(6979):190-3. PubMed ID: 15014502
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylation of Ser72 is dispensable for Skp2 assembly into an active SCF ubiquitin ligase and its subcellular localization.
Bashir T; Pagan JK; Busino L; Pagano M
Cell Cycle; 2010 Mar; 9(5):971-4. PubMed ID: 20160477
[TBL] [Abstract][Full Text] [Related]
7. Targeting the Ubiquitin-Proteasome System and Recent Advances in Cancer Therapy.
Spano D; Catara G
Cells; 2023 Dec; 13(1):. PubMed ID: 38201233
[TBL] [Abstract][Full Text] [Related]
8. Neosetophomone B induces apoptosis in multiple myeloma cells via targeting of AKT/SKP2 signaling pathway.
Kuttikrishnan S; Ahmad F; Mateo JM; Prabhu KS; El-Elimat T; Oberlies NH; Pearce CJ; Akil ASA; Bhat AA; Alali FQ; Uddin S
Cell Biol Int; 2024 Feb; 48(2):190-200. PubMed ID: 37885161
[TBL] [Abstract][Full Text] [Related]
9. Promoter methylation and enhanced SKP2 are associated with the downregulation of CDKN1C in cervical squamous cell carcinoma.
Roychowdhury A; Pal D; Basu M; Samadder S; Mondal R; Roy A; Roychoudhury S; Panda CK
Cell Signal; 2023 Sep; 109():110735. PubMed ID: 37257769
[TBL] [Abstract][Full Text] [Related]
10. Small-molecule compounds inhibiting S-phase kinase-associated protein 2: A review.
Jing J; Rui L; Junyuan S; Jinfeng Y; Zhihao H; Weiguo L; Zhenyu J
Front Pharmacol; 2023; 14():1122008. PubMed ID: 37089937
[TBL] [Abstract][Full Text] [Related]
11. The roles of E3 ubiquitin ligases in cancer progression and targeted therapy.
Sampson C; Wang Q; Otkur W; Zhao H; Lu Y; Liu X; Piao HL
Clin Transl Med; 2023 Mar; 13(3):e1204. PubMed ID: 36881608
[TBL] [Abstract][Full Text] [Related]
12. MESP2 binds competitively to TCF4 to suppress gastric cancer progression by regulating the SKP2/p27 axis.
Ge L; Zhao G; Lan C; Song H; Qi D; Huang P; Ke X; Cui H
Cell Death Discov; 2023 Mar; 9(1):79. PubMed ID: 36854722
[TBL] [Abstract][Full Text] [Related]
13. Awareness on hematological malignancies among college students.
Jibu RM; Veeraraghavan VP; Gayathri R; Kavitha S
J Adv Pharm Technol Res; 2022 Dec; 13(Suppl 2):S534-S538. PubMed ID: 36798560
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
